Adagene Inc. develops antibody-based cancer immunotherapies as a Nasdaq-listed foreign issuer whose securities trade as ADSs under ADAG. The company uses computational biology and artificial intelligence through its proprietary Dynamic Precision Library platform, including NEObody, SAFEbody and POWERbody technologies, to design masked and engineered antibody programs.
Recurring company updates center on muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody, clinical data in microsatellite stable colorectal cancer and hepatocellular carcinoma, combination studies with checkpoint and bispecific therapies, and FDA Fast Track designation in MSS metastatic colorectal cancer. Other developments include scientific meeting presentations, SAFEbody collaborations and licensing, advisory board changes, financial results and ADS capital offerings.
Adagene Inc. (Nasdaq: ADAG) will participate in several upcoming investor conferences, including a live Fireside Chat at the Jefferies Global Healthcare Conference on June 8 at 4:30 p.m. ET and one-on-one meetings at the Goldman Sachs Annual Global Healthcare Conference on June 13. Additionally, Adagene will engage in virtual meetings during the ICA 2nd Annual Asia Pacific Healthcare Conference from May 18-24 and the Berenberg Emerging Biotech Conference on May 19. The company focuses on developing novel antibody-based cancer immunotherapies utilizing advanced technologies.
Adagene Inc. (Nasdaq: ADAG) presented promising preclinical data at the AACR Annual Meeting 2022, showcasing its new antibody candidates designed for improved cancer therapy. The showcased candidates include ADG206, a masked anti-CD137 therapy, ADG153, a masked anti-CD47 antibody, and ADG138, a HER2×CD3 bispecific T-cell engager. All candidates incorporate SAFEbody technology for enhanced safety and efficacy. IND filings for ADG206 and ADG153 are expected in 2022, marking a significant milestone towards advancing these innovative therapies.
Adagene Inc. (ADAG) reported significant advancements in its pipeline, focusing on anti-CTLA-4 programs ADG116 and ADG126. The company established a strategic collaboration with Sanofi valued at over $2.5 billion, enhancing its SAFEbody technology platform. For 2021, net revenue surged to $10.2 million from $0.7 million in 2020, bolstered by licensing agreements. Despite a net loss of $73.2 million attributable to increased R&D expenses, Adagene maintains a strong cash position of $174.4 million, supporting its ambitious development plans for 2022.
Adagene Inc. (Nasdaq: ADAG) has received FDA clearance to initiate a Phase 1b/2 clinical trial for its anti-CTLA-4 monoclonal antibody, ADG126, in combination with pembrolizumab. The ADG126-P001 trial will take place at multiple sites in the U.S. and Asia Pacific and aims to treat patients with advanced solid tumors. ADG126 utilizes SAFEbody technology for enhanced targeting in the tumor microenvironment, aiming to improve safety and efficacy profiles. The trial is set to begin soon with a focus on dose escalation and early efficacy evaluation.
Adagene Inc. (Nasdaq: ADAG) announced advancements in its cancer immunotherapy pipeline, revealing four abstracts for the AACR Annual Meeting 2022. These presentations detail promising preclinical data for three product candidates: ADG138, ADG206, and ADG153. Utilizing its AI-driven platform, Adagene aims to enhance safety and efficacy through POWERbody technology, integrating SAFEbody® precision masking. Findings suggest effective immunotherapy for solid tumors via innovative approaches in antibody development. The meeting takes place from April 8-13, 2022, in New Orleans.
Adagene Inc. (Nasdaq: ADAG) has announced a collaboration and exclusive licensing agreement with Sanofi for the development of masked monoclonal and bispecific antibodies.
Sanofi will pay Adagene $17.5 million upfront and could lead to potential milestone payments totaling $2.5 billion. Adagene will focus on early-stage research using its SAFEbody technology, which targets tumors while minimizing toxicity. This partnership aims to address unmet needs in oncology, leveraging Adagene's AI-driven platform and extensive preclinical research.
Adagene Inc. (Nasdaq: ADAG) will participate in one-on-one investor meetings and provide a corporate update at the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. The presentation is scheduled for February 17 at 11:20 a.m. ET. Investors can access a webcast of the presentation on Adagene's website for 30 days. Adagene focuses on developing novel antibody-based cancer immunotherapies utilizing its Dynamic Precision Library platform, which includes NEObody™, SAFEbody®, and POWERbody™ technologies.
Adagene Inc. (Nasdaq: ADAG) has announced strategic board and management appointments to drive its growth in antibody-based therapies. Liu Yuwen joins as an independent board member, while Jiping Zha, M.D., Ph.D., and Dana Hu-Lowe, Ph.D., have been appointed as Executive Vice President of Clinical Development and Vice President of Global Product Team Leadership, respectively. These changes come as the company prepares to leverage its AI-powered antibody technology platform for rapid pipeline growth and capitalize on industry opportunities.
Adagene Inc. (Nasdaq: ADAG) announced the dosing of the first patient in a phase 1b/2 trial for its anti-CD137 agonist ADG106 combined with anti-CTLA-4 mAb ADG116, targeting advanced solid tumors. This trial aims to evaluate safety and tolerability of the innovative combination, addressing unmet needs in cancer therapies. Both ADG106 and ADG116 have shown strong safety profiles and early efficacy signals in previous trials. The study is expected to set a new precedent for combination therapies in oncology, aligning with Adagene's mission to advance antibody-based cancer treatments.
Adagene Inc. (Nasdaq: ADAG) has appointed Dr. David Gandara to its Scientific and Strategic Advisory Board. Dr. Gandara is known for his expertise in cancer drug development and biomarker strategies. He expressed enthusiasm for Adagene's potential in advancing immuno-oncology treatments. Adagene CEO Peter Luo highlighted Gandara's insights as valuable, especially concerning the trial of ADG106 in combination with Nivolumab for non-small cell lung cancer. Dr. Gandara's extensive credentials enhance Adagene's leadership in the immunotherapy field.